D-γ-bromo-isovaleric acid methyl ester | 59147-45-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: D-γ-bromo-isovaleric acid methyl ester
• 英文别名: D-γ-Brom-isovaleriansaeure-methylester；(S)-methyl 4-bromo-3-methylbutanoate；Methyl (S)-4-bromo-3-methylbutanoate；methyl (3S)-4-bromo-3-methylbutanoate
• CAS: 59147-45-4；86693-71-2
• 化学式: C₆H₁₁BrO₂
• 分子量: 195.056
• InChiKey: GQZJJQSGDFIXQM-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  D-γ-bromo-isovaleric acid methyl ester 在 甲醇 、 sodium methylate 作用下， 生成 Cyclopropanecarboxylic acid, 2-methyl-, methyl ester, cis-
  参考文献：
  名称：

  Hospital-acquired infections among chronic hemodialysis patients

  摘要：

  The epidemiological characteristics of nosocomial infections among patients requiring chronic hemodialysis, a high-risk and rapidly growing population, have not been fully elucidated. During a 30 month cohort study, rates of bloodstream infections (BSIs), urinary tract infections (UTIs), pneumonia, and diarrhea caused by Clostridium difficile and the distribution of pathogens among hospitalized chronic hemodialysis patients were compared with hospitalized patients not requiring chronic hemodialysis, To identify risk factors for developing a nosocomial infection among chronic hemodialysis patients, a matched case-control study was performed. A total of 1,557 nosocomial infections were detected during 1,317 of 68,361 admissions (2%). Of these, 47 nosocomial infections occurred in chronic hemodialysis patients during 31 of 578 admissions (5%). Nosocomial infections were significantly more frequent among the chronic hemodialysis group (9.1/1,000 patient-days) compared with the non-chronic hemodialysis group (3.8/1,000 patient-days; relative risk [RR], 2.4; 95% confidence interval [CI], 1.8 to 3.2; P < 0.001). UTIs were the most common nosocomial infections among chronic hemodialysis patients, accounting for 47% of all infections in this population. UTIs were significantly more common among chronic hemodialysis patients (4.2/1,000 patient-days) compared with non-chronic hemodialysis patients (0.7/1,000 patient-days; RR, 6.2; 95% CI, 3.8 to 9.5; P < 0.001). Among chronic hemodialysis patients, Candida spp and enterococci were the most common pathogens in contrast to coagulase-negative staphylococci and Staphylococcus aureus among patients not requiring hemodialysis. Using conditional logistic regression, a greater index of comorbidity was significantly associated with nosocomial infections among the chronic hemodialysis population (odds ratio, 3.6; 95% CI, 1.2 to 10.7; P = 0.02), Chronic hemodialysis patients are at a substantially greater risk for developing a nosocomial infection compared with other hospitalized patients. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(00)70044-8
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 四氯化碳 、 溴 作用下， 生成 D-γ-bromo-isovaleric acid methyl ester
  参考文献：
  名称：

  Hospital-acquired infections among chronic hemodialysis patients

  摘要：

  The epidemiological characteristics of nosocomial infections among patients requiring chronic hemodialysis, a high-risk and rapidly growing population, have not been fully elucidated. During a 30 month cohort study, rates of bloodstream infections (BSIs), urinary tract infections (UTIs), pneumonia, and diarrhea caused by Clostridium difficile and the distribution of pathogens among hospitalized chronic hemodialysis patients were compared with hospitalized patients not requiring chronic hemodialysis, To identify risk factors for developing a nosocomial infection among chronic hemodialysis patients, a matched case-control study was performed. A total of 1,557 nosocomial infections were detected during 1,317 of 68,361 admissions (2%). Of these, 47 nosocomial infections occurred in chronic hemodialysis patients during 31 of 578 admissions (5%). Nosocomial infections were significantly more frequent among the chronic hemodialysis group (9.1/1,000 patient-days) compared with the non-chronic hemodialysis group (3.8/1,000 patient-days; relative risk [RR], 2.4; 95% confidence interval [CI], 1.8 to 3.2; P < 0.001). UTIs were the most common nosocomial infections among chronic hemodialysis patients, accounting for 47% of all infections in this population. UTIs were significantly more common among chronic hemodialysis patients (4.2/1,000 patient-days) compared with non-chronic hemodialysis patients (0.7/1,000 patient-days; RR, 6.2; 95% CI, 3.8 to 9.5; P < 0.001). Among chronic hemodialysis patients, Candida spp and enterococci were the most common pathogens in contrast to coagulase-negative staphylococci and Staphylococcus aureus among patients not requiring hemodialysis. Using conditional logistic regression, a greater index of comorbidity was significantly associated with nosocomial infections among the chronic hemodialysis population (odds ratio, 3.6; 95% CI, 1.2 to 10.7; P = 0.02), Chronic hemodialysis patients are at a substantially greater risk for developing a nosocomial infection compared with other hospitalized patients. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(00)70044-8

文献信息

• [EN] SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF<br/>[FR] PIPÉRIDINES SUBSTITUÉES QUI ACCROISSENT L'ACTIVITÉ DE P53, ET UTILISATIONS DE CES COMPOSÉS
  申请人：SCHERING CORP

  公开号：WO2011046771A1

  公开（公告）日：2011-04-21

  The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

  本发明提供了如下所述的化合物的化学式（1）或其药学上可接受的盐、溶剂合物或酯。这些化合物可用作HDM2蛋白的抑制剂。还公开了包含上述化合物的药物组合物以及使用它们治疗癌症的方法。
• SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF
  申请人：Bogen Stephane L.

  公开号：US20120208844A1

  公开（公告）日：2012-08-16

  The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

  本发明提供了一种如下式（1）所述的化合物或其药学上可接受的盐，溶剂或酯。该化合物可用作HDM2蛋白的抑制剂。还揭示了包含上述化合物的药物组合物以及使用它们治疗癌症的方法。
• SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140336222A1

  公开（公告）日：2014-11-13

  The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

  本发明提供了一种如下所述的化合物1的药物可接受的盐、溶剂或酯。这些化合物可用作HDM2蛋白的抑制剂。还揭示了包括上述化合物的制药组合物以及使用它们治疗癌症的方法。
• US8859776B2
  申请人：——

  公开号：US8859776B2

  公开（公告）日：2014-10-14
• Hospital-acquired infections among chronic hemodialysis patients
  作者：Erika M.C. D'Agata、David B. Mount、Valerie Thayer、William Schaffner

  DOI：10.1016/s0272-6386(00)70044-8

  日期：2000.6

  The epidemiological characteristics of nosocomial infections among patients requiring chronic hemodialysis, a high-risk and rapidly growing population, have not been fully elucidated. During a 30 month cohort study, rates of bloodstream infections (BSIs), urinary tract infections (UTIs), pneumonia, and diarrhea caused by Clostridium difficile and the distribution of pathogens among hospitalized chronic hemodialysis patients were compared with hospitalized patients not requiring chronic hemodialysis, To identify risk factors for developing a nosocomial infection among chronic hemodialysis patients, a matched case-control study was performed. A total of 1,557 nosocomial infections were detected during 1,317 of 68,361 admissions (2%). Of these, 47 nosocomial infections occurred in chronic hemodialysis patients during 31 of 578 admissions (5%). Nosocomial infections were significantly more frequent among the chronic hemodialysis group (9.1/1,000 patient-days) compared with the non-chronic hemodialysis group (3.8/1,000 patient-days; relative risk [RR], 2.4; 95% confidence interval [CI], 1.8 to 3.2; P < 0.001). UTIs were the most common nosocomial infections among chronic hemodialysis patients, accounting for 47% of all infections in this population. UTIs were significantly more common among chronic hemodialysis patients (4.2/1,000 patient-days) compared with non-chronic hemodialysis patients (0.7/1,000 patient-days; RR, 6.2; 95% CI, 3.8 to 9.5; P < 0.001). Among chronic hemodialysis patients, Candida spp and enterococci were the most common pathogens in contrast to coagulase-negative staphylococci and Staphylococcus aureus among patients not requiring hemodialysis. Using conditional logistic regression, a greater index of comorbidity was significantly associated with nosocomial infections among the chronic hemodialysis population (odds ratio, 3.6; 95% CI, 1.2 to 10.7; P = 0.02), Chronic hemodialysis patients are at a substantially greater risk for developing a nosocomial infection compared with other hospitalized patients. (C) 2000 by the National Kidney Foundation, Inc.